Nutra Pharma Corp. · OTC:NPHC
Nutra Pharma — Investor Presentation (September 2010)
26 slides from Nutra Pharma's investor presentation, September 2010
Slide 1: Corporate Presentation September 2010
CORPORATE PRESENTATION September 2010 2776 University Drive Coral Springs, FL USA Phone: (954) 509-0911 Fax: (877) 895-5647 investor.relations@NutraPharma.com www.NutraPharma.com
Slide 2: Safe Harbor
NUTRA PHARMA CORPORATION SAFE HARBOR Statements made in the course of this presentation that state the Company’s or management’s intentions, hopes, beliefs, expectations or predictions of the future are forward-looking statements. It is important to note that the Company’s actual results could diffe
Slide 3: Overview
OVERVIEW Nutra Pharma is a biotechnology company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases.
Slide 4: Nutra Pharma Overview: Introduction
NUTRA PHARMA OVERVIEW INTRODUCTION Nutra Pharma, through its subsidiaries, carries out basic drug discovery research and clinical development. The Company also manufactures, through its subsidiary over-the- counter (OTC) drug products for the treatment of moderate to severe chronic pain. These pain
Slide 5: Management Team
NUTRA PHARMA OVERVIEW MANAGEMENT TEAM Name Rik J. Deitsch Chairman and Chief Executive Officer, Nutra Pharma Paul F. Reid, Ph.D. Chief Executive Officer, ReceptoPharm Neil Roth President, Designer Diagnostics
Slide 6: Board of Directors
NUTRA PHARMA OVERVIEW BOARD OF DIRECTORS Name Rik J. Deitsch Chairman and Chief Executive Officer, Nutra Pharma Harold H. Rumph Director Dr. Stewart Lonky, MD Director Garry R. Pottruck Director
Slide 7: Marketed Pain Relievers
MARKETED PAIN RELIEVERS Nutra Pharma manufactures and markets over-the- counter (OTC) drug products for the treatment of moderate to severe chronic pain. These products are sold under the Cobroxin and Nyloxin brands.
Slide 8: Cobroxin Overview
PAIN PRODUCTS COBROXIN OVERVIEW Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat Stage 2 (moderate to severe) chronic pain. Cobroxin was launched in August 2009 and is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain,
Slide 9: Cobroxin Retailers
PAIN PRODUCTS COBROXIN OVERVIEW Cobroxin is currently sold at the following retailers:
Slide 10: Nyloxin Overview
PAIN PRODUCTS NYLOXIN OVERVIEW Nyloxin is available an over-the-counter (OTC) pain reliever clinically proven to treat Stage 2 (moderate to severe) and Stage 3 (severe) chronic pain. Nyloxin was launched in mid-2010 as an oral spray for treating back pain, neck pain, headaches, joint pain, migraines
Slide 11: Pain Products: Market Potential
PAIN PRODUCTS MARKET POTENTIAL Pain is the single most common reason patients seek medical care and accounts for half of all physician office visits in the United States. According to the American Pain Foundation, each year, more than 25 million people in the United States experience acute pain as a
Slide 12: Drug Discovery
DRUG DISCOVERY Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, conducts research into a number of products with applications for neurological, immunological, autoimmune and viral conditions.
Slide 13: Drug Discovery Overview
DRUG DISCOVERY DRUG DISCOVERY OVERVIEW Nutra Pharma’s wholly-owned subsidiary, ReceptoPharm, is developing proprietary therapeutic protein products for the billion-dollar biologics market. The Company has two leading drug candidates: RPI-MN and RPI-78M. RPI-MN RPI-MN inhibits the entry of several vi
Slide 14: Benefits of RPI-MN and RPI-78M
DRUG DISCOVERY BENEFITS OF RPI-MN AND RPI-78M RPI-MN and RPI-78M possess several desirable properties as drugs: 1. They lack measurable toxicity but are still capable of attaching to and affecting the target site on the nerve cells. This means that patients cannot overdose. 2. They display no seriou
Slide 15: Specific Benefits of RPI-MN
DRUG DISCOVERY SPECIFIC BENEFITS OF RPI-MN Benefits of Nutra Pharma’s HIV/AIDs Treatment RPI-MN Fuzeon by Roche/Trimeris Mutations are not Created Mutations are Created Relatively Inexpensive Very Expensive – Twice Current Therapies No Significant Adverse Side Effects Adverse Side Effects Present –
Slide 16: Specific Benefits of RPI-78M
DRUG DISCOVERY SPECIFIC BENEFITS OF RPI-78M Benefits of Nutra Pharma’s Multiple Sclerosis (MS) Treatment RPI-78M Competitive Drugs Disease Progress Stops Disease Progression Only Slows Patient Condition Improves No Claims Against Patient Improvement No Significant Adverse Side Effects Adverse Side E
Slide 17: Research & Development Pipeline
DRUG DISCOVERY RESEARCH & DEVELOPMENT PIPELINE ReceptoPharm's research and development pipeline consists of several novel therapies in various stages of development to prevent and/or treat Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN), Herpes, Rheumatoid Ar
Slide 18: Published Research
DRUG DISCOVERY PUBLISHED RESEARCH Cobratoxin Inhibits Pain-Evoked Discharge of Neurons in Thalamic Parafascicular Nucleus in Rats: Involvement of cholinergic and serotonergic systems // Toxicon (April 2009) Alpha Cobratoxin as a Possible Therapy for Multiple Sclerosis: A Review of the Literature lea
Slide 19: Contract Research Services
CONTRACT RESEARCH SERVICES ReceptoPharm has installed the pathways to develop, produce and supply clinical material for Phase I and II studies at the highest levels. In 2008, the Company began offering services catering to small and start-up biotechnology companies.
Slide 20: Partnering with ReceptoPharm
CONTRACT RESEARCH SERVICES PARTNERING WITH RECEPTOPHARM As a clinical stage company specializing in biologics, ReceptoPharm has cleared many of the hurdles that face emerging biotech companies. Below are the top reasons that companies choose to partner with ReceptoPharm as its CRO: 1. Therapeutic ex
Slide 21: A Global View on Drug Development
CONTRACT RESEARCH SERVICES A GLOBAL VIEW ON DRUG DEVELOPMENT ReceptoPharm prides itself on taking a global view on drug development; whether it’s preparing submissions, protocols, formulations, or organizing clinical trials internationally. ReceptoPharm has invested heavily in establishing its own p
Slide 22: Top-Rated Drug Production Facilities
CONTRACT RESEARCH SERVICES TOP-RATED DRUG PRODUCTION FACILITIES Establishing and maintaining a qualified drug production facility can represent a significant drain on a small company’s resources. ReceptoPharm understands that its investment in manufacturing and its first-hand knowledge in drug disco
Slide 23: Pre-Production Studies and Contract Manufacturing Services
CONTRACT RESEARCH SERVICES PRE-PRODUCTION STUDIES CONTRACT MANUFACTURING SERVICES Stability Studies Drug Formulation Formulation ISO 5 Sterile Filling Suite, Single and Multi-Dose Adventitious Viral Testing Liquids for Injection Preservative Efficacy Testing Clinical Trial Supplies to
Slide 24: Medical Devices
MEDICAL DEVICES Nutra Pharma’s wholly-owned drug discovery subsidiary, Designer Diagnostics, is a biotechnology sales and marketing company founded for the sale of diagnostics test kits for infectious diseases.
Slide 25: Leading Test Kit Technology
TEST KIT TECHNOLOGY LEADING TEST KIT TECHNOLOGY Designer Diagnostics Test Kits provide a highly cost effective, highly efficient, low infrastructure solution for identifying and testing sensitivity of Nontuberculous Mycobacteria (NTM) that are capable of utilizing paraffin wax as a sole carbon sourc
Slide 26: Contact Nutra Pharma
CONTACT NUTRA PHARMA 2776 University Drive Coral Springs, FL 33065 Phone: (954) 509-0911 Fax: (877) 895-5647 investor.relations@NutraPharma.com www.NutraPharma.com
Nutra Pharma — Investor Presentation (September 2010) on 6ix